eprazinone : A member of the class of piperazines in which the two amino hydrogens of piperazine are replaced by 2-benzoylpropyl and 2-ethoxy-2-phenylethyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
183C91: active metabolite of zolmitriptan [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3245 |
| CHEMBL ID | 1885437 |
| CHEBI ID | 82716 |
| SCHEMBL ID | 20156 |
| MeSH ID | M0050904 |
| PubMed CID | 178536 |
| SCHEMBL ID | 7817210 |
| MeSH ID | M0050904 |
| Synonym |
|---|
| eprazinona [inn-spanish] |
| eprazinone [inn:dcf] |
| eprazinonum [inn-latin] |
| brn 0844684 |
| 1-propanone, 3-(4-(2-ethoxy-2-phenylethyl)-1-piperazinyl)-2-methyl-1-phenyl- |
| 3-(4-(beta-ethoxyphenethyl)-1-piperazinyl)-2-methylpropiophenone |
| eprazinone |
| propiophenone, 2-(4-(beta-ethoxyphenethyl)-1-piperazinyl)methyl- |
| 1-(2-phenyl-2-ethoxyethyl)-4-(2-benzyloxypropyl)piperazine |
| 3-(4-(2-ethoxy-2-phenylethyl)-1-piperazinyl)-2-methyl-1-phenyl-1-propanone |
| einecs 233-873-3 |
| 3-[4-(2-ethoxy-2-phenyl-ethyl)piperazin-1-yl]-2-methyl-1-phenyl-propan-1-one |
| 3-[4-(2-ethoxy-2-phenylethyl)-1-piperazinyl]-2-methyl-1-phenyl-1-propanone, dihydrochloride |
| NCGC00167445-01 |
| eprazinone (inn) |
| 10402-90-1 |
| D07902 |
| AKOS005066066 |
| 3-[4-(2-ethoxy-2-phenylethyl)piperazin-1-yl]-2-methyl-1-phenylpropan-1-one |
| eprazinona |
| 883ynl63wu , |
| unii-883ynl63wu |
| 5-23-02-00216 (beilstein handbook reference) |
| eprazinonum |
| 3-(4-(2-ethoxy-2-phenylethyl)piperazin-1-yl)-2-methyl-1-phenylpropan-1-one |
| CHEMBL1885437 |
| chebi:82716 , |
| FT-0630382 |
| eprazinone [inn] |
| eprazinone [mi] |
| 3-(4-(.beta.-ethoxyphenethyl)-1-piperazinyl)-2-methylpropiophenone |
| eprazinone [who-dd] |
| SCHEMBL20156 |
| DTXSID1048336 |
| 1-propanone, 3-[4-(2-ethoxy-2-phenylethyl)-1-piperazinyl]-2-methyl-1-phenyl- |
| BSHWLCACYCVCJE-UHFFFAOYSA-N |
| propiophenone, 2-(4-(.beta.-ethoxyphenethyl)-1-piperazinyl)methyl- |
| 3-[4-(.beta.-ethoxyphenylethyl)-1-piperazinyl]-2-methylpropiophenone |
| AB01565801_02 |
| DB08990 |
| J-001095 |
| SR-01000945262-1 |
| sr-01000945262 |
| 3-[4-(2-ethoxy-2-phenylethyl)-1-piperazinyl]-2-methyl-1-phenyl-1-propanone, aldrichcpr |
| mfcd00866843 |
| AS-73208 |
| eprazinon |
| NCGC00167445-03 |
| 3-[4-(2-ethoxy-2-phenyl-ethyl)piperazin-1-yl]-2-methyl-1-phenyl-propan-1-one;3-[4-(2-ethoxy-2-phenyl-ethyl)piperazin-1-yl]-2-methyl-1-phenyl-propan-1-one |
| Q389207 |
| F15043 |
| 3-(4-(1-phenylethoxy)-3-ethylpiperazin-1-yl)-2-methyl-1-phenylpropan-1-one |
| A851213 |
| (4s)-4-[[3-[2-(methylamino)ethyl]-1h-indol-5-yl]methyl]-1,3-oxazolidin-2-one |
| 183c91 |
| 139264-35-0 |
| up93v5rs6k , |
| unii-up93v5rs6k |
| 2-oxazolidinone, 4-((3-(2-(methylamino)ethyl)-1h-indol-5-yl)methyl)-, (s)- |
| n-desmethyl zolmitriptan |
| (4s)-4-[[3-[2-(methylamino)ethyl]-1h-indol-5-yl]methyl-2-oxazolidinone |
| (s)-4-((3-(2-(methylamino)ethyl)-1h-indol-5-yl(methyl)oxazolidin-2-one |
| zolmitriptan impurity g [ep impurity] |
| 2-oxazolidinone, 4-((3-(2-(methylamino)ethyl)-1h-indol-5-yl)methyl)-, (4s)- |
| SCHEMBL7817210 |
| J-007258 |
| DTXSID00930414 |
| 4-({3-[2-(methylamino)ethyl]-1h-indol-5-yl}methyl)-4,5-dihydro-1,3-oxazol-2-ol |
| n-desmethyl zolmitriptan hcl |
| 2-oxazolidinone, 4-[[3-[2-(methylamino)ethyl]-1h-indol-5-yl]methyl]-, (4s)- |
| (4s)-4-({3-[2-(methylamino)ethyl]-1h-indol-5-yl}methyl)-1,3-oxazolidin-2-one |
| Q27291183 |
| AKOS040755021 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Cmax and AUC of oral zolmitriptan were dose-proportional and there was a 13 and 16% fall in mean zolmitriptan Cmax and AUC, respectively, when administered after food." | ( The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. Allanson, J; Hefting, NR; Jonkman, JH; Peck, RW; Seaber, EJ; Smith, DA; Sollie, FA; van Lier, JJ; Wemer, J, 1998) | 0.3 |
| " Plasma levels were maintained at a plateau between 1 and 6 hours postdose, then decreased with a half-life of approximately 3 hours." | ( Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers. Dixon, R; Nairn, K; Seaber, E; Yates, R, 2002) | 0.31 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| "At therapeutic doses zolmitriptan has good oral bioavailability in healthy volunteers and has dose-proportional pharmacokinetics that are not affected by food to any clinically relevant extent." | ( The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. Allanson, J; Hefting, NR; Jonkman, JH; Peck, RW; Seaber, EJ; Smith, DA; Sollie, FA; van Lier, JJ; Wemer, J, 1998) | 0.3 |
| Role | Description |
|---|---|
| mucolytic | A compound that alters the structure of mucus so as to decrease its viscosity and thereby facilitate its removal by ciliary action and expectoration. Compare with antitussives, which suppress the cough reflex, and expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| N-alkylpiperazine | |
| ether | An organooxygen compound with formula ROR, where R is not hydrogen. |
| aromatic ketone | A ketone in which the carbonyl group is attached to an aromatic ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 36.1254 | 0.0056 | 12.3677 | 36.1254 | AID624032 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 11 (45.83) | 18.7374 |
| 1990's | 3 (12.50) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 4 (16.67) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (49.76) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (25.00%) | 5.53% |
| Trials | 3 (60.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 3 (15.00%) | 4.05% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (60.00%) | 84.16% |
| Other | 2 (40.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||